Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026

The global peptide drug market is expected to surpass US$ 50 Billion by 2026 as per recent report "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" published by PNS Pharma. Report gives comprehensive insight on ongoing clinical trials of more than 800 peptide drugs across the globe. Report has more than 140 graphs and charts to represent peptide clinical trials data, available drug dosage, price insight and patent information.

For Report Sample Contact: rajesh@pnspharma.com or call +91-11-47067990

Report Table of Contents

1. Introduction to Peptide Therapeutics
1.1 Overview & Historical Development
1.2 Why We Need Peptide Therapeutics?

2. Foundation of Peptide Therapeutics
2.1 Screening of Novel Peptide Molecules
2.2 Production of Therapeutic Peptides
2.3 Regulation over Peptide Therapeutics

3. Key Aspects in Peptide Drug Development
3.1 Approaches to Overcome Peptide Associated Limitations
3.1.1 Terminal Protection
3.1.2 Non-Chemical Modifications
3.1.3 Synthetic Amino Acid Substitution & Backbone Modification
3.1.4 Computational Modifications for Improving Aqueous Solubility & Membrane
Permeability
3.2 High-Throughput Screening (HTS) for New Peptide Entity

4. Peptide Therapeutics over Traditional Molecules
4.1 Peptides v/s Biological Proteins
4.2 Peptides v/s Small Molecules

5. Global Peptide Therapeutics Market Scenario
5.1 Market Overview
5.2 Market by Region
5.2.1 North America
5.2.2 Europe
5.2.3 Asia
5.3 Peptide Therapeutic Market Segmentation by Application
5.3.1 Peptides in Imaging
5.3.2 Peptides in Diseases
5.4 Market by Route of Administration
5.4.1 Current Scenerio
5.4.2 Current Trends over Approved Peptide Products

6. Global Peptide Oncology Thereupetics Market Scenario
6.1 Market Overview
6.2 Peptide Oncology Drug Market - Regional Segmentation

7. Cancer Peptides Drug Cost, Dosage & Patent Insight
7.1 Firmagon (Degarelix)
7.2 Mepact (Mifamurtide)
7.3 Zoladex (Goserelin)
7.4 Eligard (Leuprolide)
7.5 Lupron (Leuprolide Acetate)
7.6 Plenaxis (Abarelix)
7.7 Trelstar (Treptorelin)
7.8 Decapeptyl SR (Treptorelin Acetate or Pamoate)
7.9 Octreotide
7.10 Sandostatin (Octeriotide Acetate)
7.11 Velcade (bortizomib)
7.12 Cosmegen (Dactinomycin)
7.13 Somatuline Depot (lanreotide)
7.14 Suprefact (Buserelin)
7.15 Ninlaro (Ixazomib)
7.16 Kyprolis (Carfilzomib)
7.17 Gonax (Degarelix Acetate)

8. Peptide Therapeutics in Cardiovascular Disease
8.1 Overview to Global Cardiovascular Diseases Burden
8.2 Peptide Drugs in Cardiovascular Diseases – Availability & Cost Analysis
8.3 Cardiac Peptide Therapeutics – Sales Analysis

9. Peptide Therapeutics in Metabolic Disorder
9.1 Overview to Global Metabolic Disorders Burden
9.2 Peptide Drugs for Metabolic Disorders – Availability, Cost & Dosage Analysis
9.3 Market of Metabolic Peptides
 
10. Peptide Therapeutics For Infections
10.1 Overview to Infectious Diseases
10.2 Global - HIV Infection Burden
10.3 Commercially Available Anti-Infective Peptide Drugs
10.4 Anti-Infectious Peptide Drugs - Regional & Sales Analysis

11. Peptide Therapeutics aganist CNS Disorders
11.1 Overview to CNS Disorders
11.2 Approaches for Developing Neuropeptide Drugs
11.3 Opportunities for Neuropeptide Drug Market

12. Global Peptides Drug Clinical Insight by Type
12.1 Dipeptides
12.2 Cyclic Peptides
12.3 Depsipeptides
12.4 Glucagon-Like Peptide
12.5 Glycopeptides
12.6 Insulin
12.7 Lipopeptides
12.8 Natriuretic Peptides
12.9 Neuropeptides
12.10 Oligopeptides
12.11 Opioid Peptides
12.12 Peptide Homone
12.13 Peptides
12.14 Peptide Fragments
12.15 Peptide Vaccine
12.16 Multiple Peptides

13. Global Peptide Drug Market Dynamics – Challenges & Drivers
13.1 Global Peptide Drug Market Drivers
13.2 Challenges for Global Peptide Drug Market
 
14. Global Peptide Therapeutics Market Future Panorama
14.1 Future Trends in Peptide Therapeutics
14.2 Peptides Therapeutics Market Opportunities

15. Oligopeptides Clinical Pipeline By Company, Indication & Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-I/II
15.4 Phase-II
15.5 Phase-III
15.6 Preregistration
15.7 Registered
15.8 Marketed

16. Insulin Clinical Pipeline By Company, Indication & Phase
16.1 Unknown
16.2 Research
16.3 Preclinical
16.4 Clinical
16.5 Phase-I
16.6 Phase-I/II
16.7 Phase-II
16.8 Phase-II/III
16.9 Phase-III
16.10 Preregistration
16.11 Registered
16.12 Marketed

17. Peptide Hormone Clinical Pipeline By Company, Indication & Phase
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-III
17.9 Preregistration
17.10 Marketed

18. Peptide Clinical Pipeline By Company, Indication & Phase
18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered
18.12 Marketed

19. Glucagon-Like Peptide Clinical Pipeline By Company, Indication & Phase
19.1 Preclinical
19.2 Clinical
19.3 Phase-I
19.4 Phase-II
19.5 Phase-III
19.6 Preregistration
19.7 Marketed

20. Glycopeptide Clinical Pipeline By Company, Indication & Phase
20.1 Preclinical
20.2 Phase-I
20.3 Phase-I/II
20.4 Marketed

21. Multiple Peptide Clinical Pipeline By Company, Indication & Phase
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Phase-II/III
21.6 Phase-III
21.7 Preregistration
21.8 Registered
21.9 Marketed

22. Peptide vaccine Clinical Pipeline By Company, Indication & Phase
22.1 Preclinical
22.2 Phase-I
22.3 Phase-I/II
22.4 Phase-II
22.5 Phase-III
22.6 Registered
22.7 Marketed

23. Cyclic Peptide Clinical Pipeline By Company, Indication & Phase
23.1 Unknown
23.2 Research
23.3 Preclinical
23.4 Phase-I
23.5 Phase-II
23.6 Phase-II/III
23.7 Phase-III
23.8 Preregistration
23.9 Registered
23.10 Marketed
 
24. Peptide Fragment Clinical Pipeline By Company, Indication & Phase
24.1 Research
24.2 Preclinical
24.3 Phase-I
24.4 Phase-I/II
24.5 Phase-II
24.6 Phase-II/III
24.7 Preregistration
24.8 Registered
24.9 Marketed

25. Dipeptide Clinical Pipeline By Company, Indication & Phase
25.1 Preclinical
25.2 Phase-I
25.3 Phase-I/II
25.4 Phase-II
25.5 Phase-III
25.6 Registered
25.7 Marketed

26. Opioid peptide Clinical Pipeline By Company, Indication & Phase
26.1 Phase-I/II
26.2 Phase-II
26.3 Preregistration
26.4 Registered
26.5 Marketed

27. Depsipeptide Clinical Pipeline By Company, Indication & Phase
27.1 Preclinical
27.2 Phase-I
27.3 Registered
27.4 Marketed

28. Natriuretic Peptide Clinical Pipeline By Company, Indication & Phase
28.1 Research
28.2 Phase-II
28.3 Phase-III
28.4 Marketed

29. Neuropeptide Clinical Pipeline By Company, Indication & Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
29.5 Phase-II
29.6 Marketed

30. Pituitary Gonadotropin Clinical Pipeline By Company, Indication & Phase
30.1 Unknown
30.2 Preclinical
30.3 Phase-I
30.4 Phase-II
30.5 Phase-III
30.6 Marketed

31. Lipopeptide Clinical Pipeline By Company, Indication & Phase
31.1 Research
31.2 Preclinical
31.3 Phase-II
31.4 Phase-III
 
32. Peptide Aptamer Clinical Pipeline By Company, Indication & Phase
32.1 Preclinical
32.2 Phase-I
32.3 Phase-I/II
32.4 Phase-III

33. Competitive Landscape
33.1 Amgen
33.2 Amylin Pharmaceuticals
33.3 Apitope Technology
33.4 BioPartners
33.5 BiondVax Pharmaceuticals Ltd
33.6 Boehringer Ingelheim
33.7 Circassia
33.8 Corden Pharma (Peptisyntha)
33.9 Eli Lily
33.10 Galena Biopharmaceuticals
33.11 GlaxoSmithKline
33.12 Hyperion Therapeutics
33.13 ImmunoCellular Therapeutics
33.14 Ipsen
33.15 Lonza
33.16 Merck
33.17 NovoNordisk
33.18 Par Pharmaceuticals
33.19 PeptiDream
33.20 Roche
33.21 Sanofi
33.22 Tarix Pharmaceuticals

ANSAL BUILDING
Dr. Mukherjee Nagar, India - 110009

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

This release was published on openPR.